,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,611 Gateway Blvd.,Suite 710,South San Francisco,CA,94080,United States,650 871 0761,https://www.catalystbiosciences.com,Biotechnology,Healthcare,"Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.",7,"{'maxAge': 1, 'name': 'Dr. Nassim  Usman Ph.D.', 'age': 62, 'title': 'Pres, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1752348, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5579,0.56,0.55,0.565,0.5579,0.56,0.55,0.565,1673568000,0.0,1.302213,-18.333334,116058,116058,729879,353320,353320,0.516,0.5599,800,800,20886196,0.19,1.96,Infinity,0.4406,0.33995,0.0,0.0,USD,47272192,0.0,27441796,37974900,165416,46562,1690761600,1693440000,0.0044,0.27734,0.087519996,0.3,0.0052,-0.746,1672444800,1703980800,1688083200,-47550000,-1.48,-0.03,0.15,1:15,1486944000,-2.776,NCM,EQUITY,CBIO,CBIO,"Catalyst Biosciences, Inc.","Catalyst Biosciences, Inc.",1144848600,America/New_York,EDT,-14400000,0.55,3.0,hold,6923000,0.182,-17027000,0,2.586,2.728,0,0.0,-0.22295,-1.13138,-4727625,-17439000,0.0,0.0,0.0,USD,
1,611 Gateway Blvd.,Suite 710,South San Francisco,CA,94080,United States,650 871 0761,https://www.catalystbiosciences.com,Biotechnology,Healthcare,"Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.",7,"{'maxAge': 1, 'name': 'Ms. Seline E. Miller CPA', 'age': 53, 'title': 'Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 707551, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5579,0.56,0.55,0.565,0.5579,0.56,0.55,0.565,1673568000,0.0,1.302213,-18.333334,116058,116058,729879,353320,353320,0.516,0.5599,800,800,20886196,0.19,1.96,Infinity,0.4406,0.33995,0.0,0.0,USD,47272192,0.0,27441796,37974900,165416,46562,1690761600,1693440000,0.0044,0.27734,0.087519996,0.3,0.0052,-0.746,1672444800,1703980800,1688083200,-47550000,-1.48,-0.03,0.15,1:15,1486944000,-2.776,NCM,EQUITY,CBIO,CBIO,"Catalyst Biosciences, Inc.","Catalyst Biosciences, Inc.",1144848600,America/New_York,EDT,-14400000,0.55,3.0,hold,6923000,0.182,-17027000,0,2.586,2.728,0,0.0,-0.22295,-1.13138,-4727625,-17439000,0.0,0.0,0.0,USD,
2,611 Gateway Blvd.,Suite 710,South San Francisco,CA,94080,United States,650 871 0761,https://www.catalystbiosciences.com,Biotechnology,Healthcare,"Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.",7,"{'maxAge': 1, 'name': 'Ms. Ana  Kapor', 'title': 'Sr. Director of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5579,0.56,0.55,0.565,0.5579,0.56,0.55,0.565,1673568000,0.0,1.302213,-18.333334,116058,116058,729879,353320,353320,0.516,0.5599,800,800,20886196,0.19,1.96,Infinity,0.4406,0.33995,0.0,0.0,USD,47272192,0.0,27441796,37974900,165416,46562,1690761600,1693440000,0.0044,0.27734,0.087519996,0.3,0.0052,-0.746,1672444800,1703980800,1688083200,-47550000,-1.48,-0.03,0.15,1:15,1486944000,-2.776,NCM,EQUITY,CBIO,CBIO,"Catalyst Biosciences, Inc.","Catalyst Biosciences, Inc.",1144848600,America/New_York,EDT,-14400000,0.55,3.0,hold,6923000,0.182,-17027000,0,2.586,2.728,0,0.0,-0.22295,-1.13138,-4727625,-17439000,0.0,0.0,0.0,USD,
